[go: up one dir, main page]

WO2000019993A3 - Methodes et compositions permettant de reduire la surproduction mitochondriale d'especes oxygenees reactives dans des cellules - Google Patents

Methodes et compositions permettant de reduire la surproduction mitochondriale d'especes oxygenees reactives dans des cellules Download PDF

Info

Publication number
WO2000019993A3
WO2000019993A3 PCT/US1999/023457 US9923457W WO0019993A3 WO 2000019993 A3 WO2000019993 A3 WO 2000019993A3 US 9923457 W US9923457 W US 9923457W WO 0019993 A3 WO0019993 A3 WO 0019993A3
Authority
WO
WIPO (PCT)
Prior art keywords
overproduction
compositions
cells
methods
oxygen species
Prior art date
Application number
PCT/US1999/023457
Other languages
English (en)
Other versions
WO2000019993A2 (fr
Inventor
Michael Brownlee
Original Assignee
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Einstein Coll Med filed Critical Einstein Coll Med
Priority to AU64218/99A priority Critical patent/AU6421899A/en
Publication of WO2000019993A2 publication Critical patent/WO2000019993A2/fr
Publication of WO2000019993A3 publication Critical patent/WO2000019993A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à un moyen d'identification des patients nécessitant un traitement empêchant le développement ou la progression de complications du diabète ou de l'hyperglycémie, complications dont la médiation est assurée par des espèces oxygénées réactives (ROS), ainsi qu'à des méthodes de traitement de tels patients. Le traitement pharmacologique consiste à administrer au patient un agent identifié comme réduisant les taux de ROS ou des indicateurs corrélés au taux de ROS, tels que les taux de LP, AGE, NFλB, PKC ou l'activation de l'aldose réductase dans des cellules non insulino-dépendantes cultivées dans des conditions à teneur en glucose élevée. Tous les agents qui sont identifiés comme étant efficaces peuvent être utilisés en tant qu'agents pharmacothérapeutiques s'ils conviennent par ailleurs d'un point de vue pharmacologique. On empêche la formation de ROS induite par l'hyperglycémie dans des cellules non insulino-dépendantes telles que les cellules endothéliales à l'aide d'agents découplants du transport d'électrons mitochondrial, d'inhibiteurs du Complexe II et d'agents mimétiques de la superoxyde-dismutase/catalase. Lesdits inhibiteurs du Complexe II et lesdits agents découplants inhibent également la peroxydation lipidique induite par l'hyperglycémie, l'activation des PKC, l'activation des NFλB, l'activité de l'aldose réductase et la formation de produits de glycoxydation intracellulaire. L'invention se rapporte également à des méthodes de thérapie génique permettant de réduire les taux de ROS et les taux associés aux ROS d'indicateurs tels que LP, AGE, l'activation des NFλB et l'activation des PKC dans des cellules non insulino-dépendantes. Des produits de synthèse de vecteurs issus de la thérapie génique, et notamment des produits de synthèse de vecteurs viraux, sont introduits dans les cellules d'un patient nécessitant un tel traitement. Ces produits de synthèse codent pour un peptide qui dissocie l'oxydation de la phosphorylation. Cette invention se rapporte également à une méthode permettant la production d'un peptide normal ou fonctionnel de remplacement d'un produit génique mitochondrial défectueux qui est identifié conformément au procédé décrit ci-dessus comme étant cliniquement associé au développement ou à la progression de complications diabétiques. Cette méthode se rapporte non seulement à une méthode de thérapie génique mitochondriale destinée à des patients nécessitant un tel traitement, mais elle se rapporte également à une méthode de sélection de mitochondries n'ayant pas muté qui consiste à transfecter une cellule avec des acides nucléiques-peptidiques comportant des séquences complémentaires de l'ADN mitochondrial qui contient un point de cassure de délétion ou une mutation de base unique en comparaison de l'ADN mitochondrial de type sauvage de sorte que la réplication de l'ADN mitochondrial est bloqué et les mitochondries avec mutations d'ADN sont éliminées.
PCT/US1999/023457 1998-10-06 1999-10-06 Methodes et compositions permettant de reduire la surproduction mitochondriale d'especes oxygenees reactives dans des cellules WO2000019993A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64218/99A AU6421899A (en) 1998-10-06 1999-10-06 Methods and compositions for decreasing mitochondrial overproduction of reactiveoxygen species in cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16718298A 1998-10-06 1998-10-06
US09/167,182 1998-10-06
US30568899A 1999-05-04 1999-05-04
US09/305,688 1999-05-04

Publications (2)

Publication Number Publication Date
WO2000019993A2 WO2000019993A2 (fr) 2000-04-13
WO2000019993A3 true WO2000019993A3 (fr) 2001-03-01

Family

ID=26862926

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/015734 WO2000023568A2 (fr) 1998-10-06 1999-07-12 Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules
PCT/US1999/023457 WO2000019993A2 (fr) 1998-10-06 1999-10-06 Methodes et compositions permettant de reduire la surproduction mitochondriale d'especes oxygenees reactives dans des cellules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015734 WO2000023568A2 (fr) 1998-10-06 1999-07-12 Procedes et compositions permettant de reduire la surproduction de mitochondries des especes oxygene reactives dans les cellules

Country Status (2)

Country Link
AU (1) AU6421899A (fr)
WO (2) WO2000023568A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470677B2 (en) 1993-10-15 2008-12-30 Aeolus Pharmaceuticals, Inc. Oxidant scavengers
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US7754706B2 (en) 2002-12-06 2010-07-13 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US7759333B2 (en) 2001-12-14 2010-07-20 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US8927691B2 (en) 2003-10-24 2015-01-06 Gencia Corporation Transducible polypeptides for modifying metabolism
US8952133B2 (en) 2003-10-24 2015-02-10 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissue

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IL144503A0 (en) 1999-01-25 2002-05-23 Nat Jewish Med & Res Center Substituted porphyrins
FR2806911B1 (fr) * 2000-03-28 2003-01-10 Univ Rene Descartes Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
WO2002098431A1 (fr) 2001-06-01 2002-12-12 National Jewish Medical And Research Center Capteurs oxydants destines au traitement du diabete ou a etre utilises dans une transplantation ou a induire une tolerance immunitaire
ES2333704T3 (es) 2001-12-13 2010-02-26 University Of Virginia Patent Foundation Transfeccion de organulos mediada por un vector.
EP1687017B1 (fr) 2003-10-24 2013-03-06 Gencia Corporation Procédés et compositions permettant de distribuer des polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
ZA200603347B (en) 2003-12-11 2009-02-25 Alcon Inc Superoxide dismutase mimics for the treatment of optic nerve and retinal damage
CA2550217A1 (fr) * 2003-12-12 2005-07-07 Michael A. Brownlee Glp-1 (9-36): methodes et compositions
JP2008500347A (ja) * 2004-05-24 2008-01-10 ニュー・ヨーク・ユニヴァーシティー 高血糖症による血糖の急激な増加及び／又は急激な遊離脂肪酸流動の増加の病理学的影響の治療方法又は予防方法
US9737511B2 (en) 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
WO2008044138A1 (fr) * 2006-10-12 2008-04-17 Syddansk Universitet Nanocapteur optique permettant la détection des espèces réactives de l'oxygène
DK2275524T3 (da) 2008-02-29 2012-01-30 Buck Chemie Gmbh Klæbemiddel til påføring på en sanitær genstand
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
KR20160036108A (ko) 2008-05-23 2016-04-01 내셔날 쥬이쉬 헬스 알킬화 종으로의 노출과 관련된 상해를 치료하는 방법
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2890370B1 (fr) 2012-08-31 2019-10-09 The Regents of the University of California Agents utiles pour le traitement de l'obésité, du diabète et de troubles associés
EP2911662A4 (fr) * 2012-10-25 2016-09-28 Technion Res & Dev Foundation Procédé de traitement d'une maladie
EP3538115A4 (fr) * 2016-11-14 2020-04-22 Memorial Sloan Kettering Cancer Center Cellules de schwann dérivées de cellules souches
WO2019055490A1 (fr) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University Conditionnement de tissu irradié pour rétention de greffe de graisse

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
WO1995010185A1 (fr) * 1993-10-15 1995-04-20 Duke University Superoxyde-dismutase et ses mimetiques
WO1996009053A1 (fr) * 1994-09-20 1996-03-28 Duke University Activite d'oxydoreductase de porphyrines manganiques
WO1996040658A1 (fr) * 1995-06-07 1996-12-19 Monsanto Company Procede de preparation de polyazamacrocycles substitues
WO1998027426A1 (fr) * 1996-12-17 1998-06-25 University Of Aberdeen Substrats exerçant un effet sur les canaux
WO1999000123A1 (fr) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Utilisation d'un medicament permettant de moduler la regulation de l'upc-2 et procede de tri de medicaments potentiels contre l'obesite
WO1999023097A1 (fr) * 1997-11-03 1999-05-14 Duke University Porphyrines substituees

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH059114A (ja) * 1990-08-29 1993-01-19 Takeda Chem Ind Ltd 糖尿病性合併症の予防・治療剤
WO1995010185A1 (fr) * 1993-10-15 1995-04-20 Duke University Superoxyde-dismutase et ses mimetiques
WO1996009053A1 (fr) * 1994-09-20 1996-03-28 Duke University Activite d'oxydoreductase de porphyrines manganiques
WO1996040658A1 (fr) * 1995-06-07 1996-12-19 Monsanto Company Procede de preparation de polyazamacrocycles substitues
WO1998027426A1 (fr) * 1996-12-17 1998-06-25 University Of Aberdeen Substrats exerçant un effet sur les canaux
WO1999000123A1 (fr) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Utilisation d'un medicament permettant de moduler la regulation de l'upc-2 et procede de tri de medicaments potentiels contre l'obesite
WO1999023097A1 (fr) * 1997-11-03 1999-05-14 Duke University Porphyrines substituees

Non-Patent Citations (47)

* Cited by examiner, † Cited by third party
Title
ALEMA G ET AL: "Preliminary experiments on the effects of the intracarotid introduction of sodium amytal in parkinsonian syndromes.", BOLL SOC ITAL BIOL SPER, (1961 OCT 31) 37 1036-7., XP000937402 *
AMBROSIO, GIUSEPPE ET AL: "Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow", J. BIOL. CHEM. (1993), 268(25), 18532-41, XP000939340 *
CALVERT A ET AL: "A double-blind evaluation of diazepam and amylobarbitone in acute myocardial infarction.", MEDICAL JOURNAL OF AUSTRALIA, (1974 OCT 26) 2 (17) 624-7., XP000937406 *
CHIERICI F ET AL: "[Clinical results of the use of a new drug association in heart diseases]. Risultati clinici dell'impiego di una nuova associazioni farmacologica nelle cardiopatie.", CLINICA TERAPEUTICA, (1970 FEB 15) 52 (3) 219-57., XP000937403 *
CURCIO, F. AND CERIELLO, A.: "Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications.", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, vol. 28A, no. 11-12, November 1992 (1992-11-01) - December 1992 (1992-12-01), pages 787 - 790, XP000879178 *
CUZZOCREA, SALVATORE ET AL: "Beneficial effects of Mn(III) tetrakis (4-benzoic acid) porphyrin ( MnTBAP ), a superoxide dismutase mimetic, n carrageenan-induced pleurisy", FREE RADICAL BIOL. MED. (1998), VOLUME DATE 1999, 26(1/2), 25-33, XP000900575 *
DATABASE WPI Section Ch Week 199308, Derwent World Patents Index; Class B05, AN 1993-061598[08], XP002131312, "New drug for preventing and treating diabetic complications comprises 1,4-benzoquinone or its hydroquinone form; treats nephropathy, neuropathy, arteriosclerosis etc." *
DAY, BRIAN J. ET AL: "Manganic porphyrins possess catalase activity and protect endothelial cells against hydrogen peroxide-mediated injury", ARCH. BIOCHEM. BIOPHYS. (1997), 347(2), 256-262, XP000900554 *
DELANTY N ET AL: "REVIEW ARTICLE. OXIDATIVE INJURY IN THE NERVOUS SYSTEM", ACTA NEUROLOGICA SCANDINAVICA,DK,MUNKSGAARD, COPENHAGEN, vol. 98, no. 3, September 1998 (1998-09-01), pages 145 - 153, XP000866110, ISSN: 0001-6314 *
DILEEPAN, KOTTARAPPAT N. ET AL: "Complete inhibition of dihydro-orotate oxidation and superoxide production by 1,1,1-trifluoro-3-thenoylacetone in rat liver mitochondria", BIOCHEM. J. (1985), 225(1), 189-94, XP000900570 *
ELLIS, E.A. ET AL.: "Increased NADH oxidase activity in the retina of the BBZ/WOR diabetic rat", FREE RADICAL BIOLOGY AND MEDICINE, vol. 24, no. 1, 1 January 1998 (1998-01-01), pages 111 - 120, XP000879172 *
GARCIA-RUIZ C. ET AL: "Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-.kappa.B: Studies with isolated mitochondria and rat hepatocytes.", MOLECULAR PHARMACOLOGY, (1995) 48/5 (825-834)., XP000900576 *
GIARDINO, I. ET AL.: "BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells.", JOURNAL OF CLINICAL INVESTIGATION, vol. 97, no. 6, March 1996 (1996-03-01), pages 1422 - 1428, XP000879169 *
HAWTIN S.R. ET AL: ".beta.-amyloid inhibition of MTT reduction is not mimicked by inhibitors of mitochondrial respiration.", BIOCHEMICAL SOCIETY TRANSACTIONS, (1995) 23/1 (56S)., XP000900574 *
HONG, C. Y. ET AL: "The inhibitory effect of some ionophores on human sperm motility", CONTRACEPTION (1986), 33(3), 301-6, XP000900566 *
IKEJIRI Y ET AL: "Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS.", NEUROLOGY, vol. 47, no. 2, 1996, pages 583 - 585, XP000900659, ISSN: 0028-3878 *
INAGAKI T. ET AL: "Psychiatric symptoms in a patient with diabetes mellitus associated with point mutation in mitochondrial DNA.", BIOLOGICAL PSYCHIATRY, (1997) 42/11 (1067-1069)., XP000900663 *
KIM J.-M. ET AL: "Clinical evaluation of idebenone (CV-2619) for the efficacy and safety in patients with cerebral atherosclerosis and sequelae of infarction.", JOURNAL OF KOREAN SOCIETY FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS, (1998) 6/1 (73-82)., XP000900723 *
KING, G.L. AND BROWNLE, M.: "The cellular and molecular mechanisms of diabetic complications", ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, vol. 25, no. 2, June 1996 (1996-06-01), pages 255 - 270, XP000878790 *
KOSOVSKII, M. I. ET AL: "In vitro sugar transport regulation by new calcium ionophores", TSITOLOGIYA (1984), 26(4), 409-14, XP000900593 *
LUFT R. ET AL: "Mitochondrial medicine.", JOURNAL OF INTERNAL MEDICINE, (1995) 238/5 (405-421)., XP000900669 *
MELOV S ET AL: "A NOVEL NEUROLOGICAL PHENOTYPE IN MICE LACKING MITOCHONDRIAL MANGANESE SUPEROXIDE DISMUTASE", NATURE GENETICS,US,NEW YORK, NY, vol. 18, no. 2, 18 February 1998 (1998-02-18), pages 159 - 163, XP000904849, ISSN: 1061-4036 *
MELOV S ET AL: "Superoxide and mitochondria: Consequences and potential therapies.", ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, vol. 31, no. SUPPL. 29, 1998, 29th Annual Meeting of the Environmental Mutagen Society;Anaheim, California, USA; March 21-26, 1998, pages 23, XP000937971, ISSN: 0893-6692 *
MIASNIKOV L A ET AL: "[The effect of certain pharmacologic substances on cholesterol metabolism in experimental atherosclerosis ]. Vliianie neirotropnykh farmakologicheskikh veshchestv na kholesterinovyi obmen pri eksperimental'nykh aterosklerozakh.", PATOLOGICHESKAIA FIZIOLOGIIA I EKSPERIMENTALNAIA TERAPIIA, (1967 NOV-DEC) 11 (6) 40-3., XP000937407 *
MIYAZAKI M ET AL: "MECHANISMS RESPONSIBLE FOR LONG-TERM SURVIVAL OF ADULT RAT HEPATOCYTES IN THE PRESENCE OF PHENOBARBITAL IN PRIMARY CULTURE", EXPERIMENTAL CELL RESEARCH, vol. 182, no. 2, 1989, pages 415 - 424, XP000937422, ISSN: 0014-4827 *
MOK J.S.L. ET AL: "Inhibition of nitrergic neurotransmission in the bovine retractor penis muscle by an oxidant stress: Effects of superoxide dismutase mimetics.", BRITISH JOURNAL OF PHARMACOLOGY, (1998) 124/1 (111-118)., XP000900565 *
NAGAI Y ET AL: "BRAIN DISTRIBUTION OF IDEBENONE CV-2619 AND ITS EFFECT ON LOCAL CEREBRAL GLUCOSE UTILIZATION IN RATS", FOLIA PHARMACOLOGICA JAPONICA, vol. 88, no. 2, 1986, pages 109 - 124, XP000900676, ISSN: 0015-5691 *
NAGAKAWA Y ET AL: "EFFECT OF IDEBENONE ON HEMORHEOLOGIC VARIABLES IN GERIATRIC PATIENTS WITH CEREBRAL INFARCTION", CLINICAL HEMORHEOLOGY, vol. 11, no. 5, 1991, pages 351 - 360, XP000900667, ISSN: 0271-5198 *
NAGAOKA A ET AL: "INHIBITORY EFFECT OF IDEBENONE CV-2619 A NOVEL COMPOUND ON VASCULAR LESIONS IN HYPERTENSIVE RATS", JAPANESE JOURNAL OF PHARMACOLOGY, vol. 36, no. 3, 1984, pages 291 - 300, XP000937975, ISSN: 0021-5198 *
NAITO M. ET AL: "Protective effects of idebenone on vascular endothelial cells against toxicity induced by oxidatively modified low density lipoprotein.", ARTERY, (1994) 20/6 (314-323)., XP000900673 *
NAPPI G ET AL: "LONG-TERM IDEBENONE TREATMENT OF VASCULAR AND DEGENERATIVE BRAIN DISORDERS OF THE ELDERLY", ARCHIVES OF GERONTOLOGY AND GERIATRICS,NL,ELSEVIER, AMSTERDAM, vol. 15, no. 3, 1 November 1992 (1992-11-01), pages 261 - 269, XP000671984, ISSN: 0167-4943 *
ODAWARA M ET AL: "The effect of idebenone on insulin secretion in elderly diabetes mellitus.", AGE (CHESTER), vol. 18, no. 3, 1995, 6th Congress of the International Association of Biomedical Gerontology;Makuhari, Japan; August 21-23, 1995, pages 140, XP000937416, ISSN: 0161-9152 *
O'DONNELL V.B. ET AL: "Role of oxidants in TNF-.alpha.-mediated cytotoxicity.", BIOCHEMICAL SOCIETY TRANSACTIONS, (1995) 23/2 (239S)., XP000900573 *
PARIS D ET AL: "ROLE OF PEROXYNITRITE IN THE VASOACTIVE AND CYTOTOXIC EFFECTS OF ALZHEIMER'S SS-AMYLOID1-40 PEPTIDE", EXPERIMENTAL NEUROLOGY,US,SAN DIEGO, CA, vol. 152, July 1998 (1998-07-01), pages 116 - 122, XP000905157 *
PARK JONG-WAN ET AL: "Role of mitochondria in oxidative damage of post-ischemic reperfused hearts.", KOREAN JOURNAL OF PHARMACOLOGY, vol. 32, no. 2, 1996, pages 201 - 209, XP000900795, ISSN: 0377-9459 *
PATEL M.: "Inhibition of neuronal apoptosis by a metalloporphyrin superoxide dismutase mimic.", JOURNAL OF NEUROCHEMISTRY, (1998) 71/3 (1068-1074)., XP000900559 *
QUILLET-MARY, ANNE ET AL: "Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis", J. BIOL. CHEM. (1997), 272(34), 21388-21395, XP000900626 *
SCHUETZ EKKEHARD ET AL: "Suppression of leukocyte-enhanced cold ischemia/reperfusion injury of liver endothelium with the benzoquinone antioxidant idebenone.", CLINICAL BIOCHEMISTRY, vol. 30, no. 8, December 1997 (1997-12-01), pages 619 - 624, XP000900660, ISSN: 0009-9120 *
SENIN U ET AL: "IDEBENONE IN SENILE DEMENTIA OF ALZHEIMER TYPE: A MULTICENTRE STUDY", ARCHIVES OF GERONTOLOGY AND GERIATRICS,NL,ELSEVIER, AMSTERDAM, vol. 15, no. 3, 1 November 1992 (1992-11-01), pages 249 - 260, XP000671985, ISSN: 0167-4943 *
SHIVARAM K ET AL: "Idebenone inhibits taurochenodeoxycholic acid toxicity and reduces oxidant stress in isolated rat hepatocytes.", GASTROENTEROLOGY, vol. 108, no. 4 SUPPL., 1995, 95th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week;San Diego, California, USA; May 14-17, 1995, pages A1169, XP000937412, ISSN: 0016-5085 *
SHOFFNER J.M. ET AL: "Oxidative phosphorylation diseases and mitochondrial DNA mutations: Diagnosis and treatment.", ANNUAL REVIEW OF NUTRITION, (1994) 14/- (535-568)., XP000900670 *
STURFELT G.; SCHELIN S.: "Acute effects of barbiturates in Parkinson's disease. A preliminary communication with case reports.", ACTA MEDICA SCANDINAVICA, vol. 201, no. 1-2, 1977, pages 75 - 76, XP000938405 *
SUNO M ET AL: "INHIBITORY EFFECTS OF A NOVEL COMPOUND IDEBENONE CV-2619 ON FREE RADICAL GENERATION AND LIPID PEROXIDATION", JOURNAL OF THE TAKEDA RESEARCH LABORATORIES, vol. 44, no. 1-2, 1985, pages 30 - 33, XP000900657, ISSN: 0371-5167 *
SZABO C. ET AL: "Evaluation of the relative contribution of nitric oxide and peroxynitrite to the suppression of mitochondrial respiration in immunostimulated macrophages using a manganese mesoporphyrin superoxide dismutase mimetic and peroxynitrite scavenger.", FEBS LETTERS, (1996) 381/1-2 (82-86)., XP000930008 *
WACHSMAN JOSEPH T: "The beneficial effects of dietary restriction: Reduced oxidative damage and enhanced apoptosis.", MUTATION RESEARCH, vol. 350, no. 1, 1996, pages 25 - 34, XP000900797, ISSN: 0027-5107 *
WEYER G ET AL: "EFFICACY AND SAFETY OF IDEBENONE IN THE LONG-TERM TREATMENT OF ALZHEIMER'S DISEASE: A DOUBLE-BLIND, PLACEBO CONTROLLED MULTICENTRE STUDY", HUMAN PSYCHOPHARMACOLOGY. CLINICAL AND EXPERIMENTAL,XX,JOHN WILEY & SONS LTD, vol. 11, no. 1, 1996, pages 53 - 65, XP000671987, ISSN: 0885-6222 *
WIELAND E ET AL: "Oxygen radicals (or) mediate the effect of white blood cells (WBC) on cytochrome P-450-3A4 (CPY3A4)-activity and -mRNA expression in a pig liver cold storage/perfusion model.", HEPATOLOGY, vol. 26, no. 4 PART 2, 1997, 48th Annual Meeting of the American Association for the Study of Liver Diseases;Chicago, Illinois, USA; November 7-11, 1997, pages 629A, XP000937417, ISSN: 0270-9139 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470677B2 (en) 1993-10-15 2008-12-30 Aeolus Pharmaceuticals, Inc. Oxidant scavengers
US7759333B2 (en) 2001-12-14 2010-07-20 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US7485721B2 (en) 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US7754706B2 (en) 2002-12-06 2010-07-13 Alcon, Inc. Superoxide dismutase mimics for the treatment of ocular disorders and diseases
US8927691B2 (en) 2003-10-24 2015-01-06 Gencia Corporation Transducible polypeptides for modifying metabolism
US8952133B2 (en) 2003-10-24 2015-02-10 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissue

Also Published As

Publication number Publication date
WO2000019993A2 (fr) 2000-04-13
AU6421899A (en) 2000-04-26
WO2000023568A2 (fr) 2000-04-27
WO2000023568A3 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
WO2000019993A3 (fr) Methodes et compositions permettant de reduire la surproduction mitochondriale d&#39;especes oxygenees reactives dans des cellules
WO2002090539A3 (fr) Compositions, methodes et trousses permettant d&#39;isoler des acides nucleiques au moyen de tensioactifs et de proteases
AU2001258701A1 (en) Systems and methods for presenting and/or converting messages
ZA200006576B (en) Methods and compositions for expression of transgenes in plants.
CA2222680A1 (fr) Agents endoparasiticides
AU2003273276A1 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2001032876A3 (fr) Compositions et techniques permettant de determiner les interactions de composants mitochondriaux et d&#39;identifier les agents modifiant ces interactions
AU2889201A (en) Automatic water toxicity measuring apparatus
WO2005000229A3 (fr) Compositions et procedes de modulation de s-nitrosoglutathion reductase
MXPA01011182A (es) Metodos, composiciones y conjuntos para indicador biologico de esterilizacion.
WO2004094675A3 (fr) Compositions et methodes permettant de determiner la presence de coronavirus du sras dans un echantillon
WO2001096604A3 (fr) Analyse de polymorphismes genetiques a l&#39;aide de marqueurs detectables a la lumiere diffusee
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
AU2002241873A1 (en) Whitening compositions containing ascomycete derived enzyme
AU2001266274A1 (en) Assay techniques based on growth stage dependent expression inc. elegans
WO2002010752A3 (fr) Puces de detection a couches multiples de polysiloxane
AU1740500A (en) Thyroid peroxidase autoantibody assay compositions, method and kit
WO2004009843A3 (fr) Detection de micro-organismes
AU2001269730A1 (en) Low carbohydrate compositions, kits thereof, and methods of use
AU2003287336A1 (en) Real-time pcr primers and probes for identification as ralstonia solanacearum race 3, biovar 2 in potato
AU2001287818A1 (en) Method and installation for opening eggs
GB9923858D0 (en) Antimicrobial compositions
WO2006128084A3 (fr) Modulation de la croissance capillaire a mediation trps1
AU2001261513A1 (en) Composition and method for increasing testosterone levels
WO2002101090A3 (fr) Procede de determination de l&#39;existence de melanges d&#39;origines animales ou vegetales dans des substrats organiques

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64218

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase